FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Prout Samantha						2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD]										Check	ationship of Reportin (all applicable) Director Officer (give title		g Person(s) to Issu 10% Owi Other (sp		ner
	`	RAPEUTICS, II	(Middle) NC.		06/	3. Date of Earliest Transaction (Month/Day/Year) 06/19/2020										X	below) below) Principal Accounting Officer				
(Street) CRANBI			08512 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indivine)	′					
		Tab	le I - Noi	n-Deriv	ative	e Se	curit	ies Ac	qu	ıired, I	Dis	posed c	of, o	r Ber	neficia	ally	Owned	I			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ar)	2A. Deemed Execution Date, if any (Month/Day/Year		,	3. Transac Code (Ir 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Securiti Benefic Owned		es ally Following	Form (D) o	n: Direct or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)		Price		Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 06				06/19	9/2020					M		3,366	5 A \$		\$10	.04	20,501		D		
Common Stock (06/19	9/2020					S ⁽¹⁾		3,366	5 D		\$1	.5	17,135		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (B)				Ex	Date Exe piration onth/Day	Date		Amo Secu Und Deri	7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		De Se (In	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da	te ercisable		xpiration ate	Title		Amoun or Numbe of Shares						
Stock Options (right to buy)	\$10.04	06/19/2020			M			3,366		(2)	0	1/02/2029		nmon ock	3,366		\$0.00	6,138		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. As of June 19, 2020, 3,366 options were fully vested and exercisable and 6,138 remained unvested from this grant.

Remarks:

/s/ Christian Formica, Attorney-in-Fact 06/23/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.